Comparing iBio (IBIO) & Its Peers

iBio (NASDAQ:IBIO) is one of 452 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its competitors? We will compare iBio to similar businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

7.9% of iBio shares are owned by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for iBio and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1	0	0	1	2.50
iBio Competitors	4797	9963	16002	371	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 113.29%. Given iBio’s competitors higher probable upside, analysts clearly believe iBio has less favorable growth aspects than its competitors.

Profitability

This table compares iBio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-126.93%	-83.06%
iBio Competitors	-2,625.49%	-359.57%	-43.35%

Valuation and Earnings

This table compares iBio and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
iBio	$400,000.00	-$18.38 million	-0.76
iBio Competitors	$440.86 million	-$69.10 million	-9.58

iBio’s competitors have higher revenue, but lower earnings than iBio. iBio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

iBio has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, iBio’s competitors have a beta of 10.24, suggesting that their average share price is 924% more volatile than the S&P 500.

Summary

iBio competitors beat iBio on 7 of the 13 factors compared.

iBio Company Profile

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.